Xbrane Reports the US FDA Acceptance of Resubmitted BLA for Lucamzi (Biosimilar, Lucentis)

Why It Matters

FDA acceptance moves Lucamzi closer to a U.S. launch, introducing competition that could lower the cost of anti‑VEGF therapy and reshape the retinal‑disease market.

Key Takeaways

• FDA set BsUFA action date for Lucamzi: Oct 29, 2026
• Resubmission addressed CRL issues identified Oct 2025
• Lucamzi approved in EU as Ximluci since 2023
• US entry could challenge Lucentis pricing and market share

Pulse Analysis

The anti‑VEGF drug Lucentis has dominated the treatment of neovascular age‑related macular degeneration and other retinal disorders for over a decade, commanding premium pricing in the United States. As clinicians seek cost‑effective alternatives, biosimilars have emerged as a strategic avenue to broaden access while preserving therapeutic efficacy. Industry analysts estimate the U.S. retinal‑disease market exceeds $5 billion annually, creating strong incentives for manufacturers to launch comparable products that can capture a share of this lucrative segment.

Swedish biotech Xbrane Biopharma has positioned its candidate Lucamzi, marketed in Europe as Ximluci, to meet that demand. Since its 2023 EU approval, the biosimilar has been available for conditions such as diabetic macular edema and macular degeneration, demonstrating comparable safety and efficacy to the reference product. After receiving a complete response letter in October 2025, Xbrane addressed the FDA’s concerns—primarily related to analytical comparability and clinical data—in a resubmitted biologics license application filed in April 2026. The agency’s acceptance and the assignment of a BsUFA action date signal regulatory progress.

The October 29, 2026 action date gives Xbrane a clear timeline to seek approval before the next fiscal cycle, potentially introducing a lower‑priced alternative to Lucentis. If approved, Lucamzi could compress pricing pressure on the incumbent, prompting Roche to consider price adjustments or value‑based contracts. Moreover, the milestone underscores the growing maturity of the biosimilar pipeline for ophthalmology, encouraging investors to allocate capital toward similar programs. For patients, the entry of a competitively priced biosimilar promises broader treatment accessibility and reduced out‑of‑pocket costs.